Gazyva obinutuzumab regulatory update

FDA approved an sBLA from Roche’s Genentech unit for Gazyva obinutuzumab to treat chronic lymphocytic leukemia (CLL)

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE